Know Cancer

or
forgot password

A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia Using a Second Generation Device


Phase 1
18 Years
N/A
Open (Enrolling)
Female
Cervical Cancer, Precancerous Condition

Thank you

Trial Information

A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia Using a Second Generation Device


OBJECTIVES:

- To identify potential improvements for a noninvasive method of diagnosing cervical
dysplasia and neoplasia using the Multispectral Digital Colposcope (MDC), a device that
uses fluorescence and reflectance spectroscopy to compare images with histopathologic
mapping of the cervical epithelium.

- To measure MDC images in vivo of the cervix using a modified device that makes
measurements in seconds rather than over 2 minutes before and after acetic acid.

- To evaluate, preliminarily, the effect of the fading of acetic acid in the image
contrast obtained over time to see if this fading can predict the grade of
intraepithelial neoplasia.

- To evaluate mapping of the cervix so that software can reconstruct the cervical
epithelial map to compare the map with routine colposcopic images as well as with those
from the MDC.

- To compare, preliminarily, MDC performance with colposcopy and pathologic analysis of
tissue removed after colposcopy in the form of the loop electrosurgical excision
procedure (LEEP).

OUTLINE: This is a multicenter study.

Patients undergo routine colposcopy as part of their regular colposcopic evaluation. The
digital colposcope is used to take images of the vagina and cervix, pre- and post-acetic
acid, using white, green, and blue light. Colposcopically abnormal areas are biopsied; a
normal area may also be biopsied. Patients undergoing loop electrosurgical excision
procedure (LEEP) may undergo one additional biopsy of a colposcopically normal site.

Inclusion Criteria


Criteria

Inclusion criteria:

- Included subjects will be ≥18 years old.

- Included subjects will not be pregnant.

- Included subjects will have a negative urine pregnancy test.

- Included subjects will be scheduled for colposcopy and/or LEEP treatment at the VGH
Women's Clinic.

- Included subjects will indicate understanding of the study.

- Included subjects will provide informed consent to participate.

Exclusion criteria:

- Individuals <18 years old will be excluded.

- Pregnant individuals will be excluded.

- Individuals that have had an operation to remove their cervix will be excluded.

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Identification of potential improvements for a noninvasive method of diagnosing cervical dysplasia and neoplasia using the Multispectral Digital Colposcope (MDC)

Safety Issue:

No

Principal Investigator

Thomas G Ehlen, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

BC Cancer Agency, Vancouver General Hospital

Authority:

United States: Institutional Review Board

Study ID:

CDR0000581295

NCT ID:

NCT00610662

Start Date:

October 2010

Completion Date:

November 2011

Related Keywords:

  • Cervical Cancer
  • Precancerous Condition
  • cervical cancer
  • cervical intraepithelial neoplasia grade 1
  • cervical intraepithelial neoplasia grade 2
  • cervical intraepithelial neoplasia grade 3
  • Neoplasms
  • Uterine Cervical Neoplasms
  • Precancerous Conditions
  • Cervical Intraepithelial Neoplasia
  • Carcinoma in Situ

Name

Location